Ag85A DNA疫苗对移植性小鼠膀胱肿瘤免疫功能的影响

目的探讨Ag85A DNA疫苗对移植性小鼠膀胱肿瘤的免疫治疗影响。方法将5~6周龄T739小鼠随机分成Ag85A DNA疫苗组(pcDNA3.1-Ag85A组)、空白质粒组(pcDNA3.1组)、生理盐水组和卡介苗组(BCG组)4组,将生长旺盛的BTT739小鼠膀胱肿瘤细胞接种于各组小鼠左后肢内侧皮下,每只1×106个细胞,荷瘤第7、14和21天于小鼠右后肢肌肉分别注射0.1mL pcDNA3.1-Ag85A,pcDNA3.1,生理盐水或BCG。荷瘤第28天处死小鼠,剥离肿瘤称重,依据公式计算肿瘤生长抑制率。利用流式细胞仪分析荷瘤小鼠脾脏T细胞亚群数量。利用酶联免疫吸附试验(ELISA)检测荷瘤小鼠血清干扰素(IFN)-γ含量。结果Ag85ADNA疫苗组肿瘤生长抑制率和T细胞亚群数量检测较空白质粒组和生理盐水组均无增高,Ag85A DNA疫苗组血清IFN-γ水平较空白质粒组和生理盐水组有所增高,但尚达不到BCG的效果。而空白质粒组和生理盐水组之间未见有意义的变化。结论尚不能认为肌肉注射Ag85A DNA疫苗可以有效提高移植性小鼠的免疫功能。

The immunological effects of Ag85A DNA vaccine in tumor-bearing mice

Objective To study the anti-bladder tumor effect of Ag85A DNA vaccine in tumor-bearing mice.Methods Agroupof5～6weeksT739micewererandomlydivided into four group:pcDNA3.1-Ag85A group,pcDNA3.1 group,NS group and BCG group.BTT739 cells(1×106)in their vigorous growth were inoculated subcutaneously into left posterior limb of each mouse in every groups.0.1 mL pcDNA3.1-Ag85A,pcDNA3.1,NS or BCG was inoculated into left posterior limb muscle at the immuned time that is the seventh day,fourteenth day and twenty-first day after tumor bearing.At the twenty-eighth day,the mice were sacrificed.The tumors were removed to measure the tumor weight and the tumor inhibition rate was calculated.Spleen was removed aseptically.The percentages of CD4+T cell and CD8+T cell were measured by flow cytometry.In addition,IFN-γ in sera of the tumor-bearing mice were assayed with indirect enzyme-linked immuno-absordent assay(ELISA).Results The results of tumor inhibition rate and the percentage of CD4+T cell,CD8+T cell and the relative value of CD4+/CD8+ showed that there wasn't difference among the Ag85A DNA vaccine group,pcDNA3.1 group and NS group.The production of IFN-γ showed that there was difference among the Ag85A DNA vaccine group,pcDNA3.1 group and NS it couldn't come up to BCG level.While the pcDNA3.1 group and NS group have no significant changes.Conclusion Intramuscular injection of Ag85A DNA vaccine may not induce the effective immunological effect in tumor-bearing.